Mahzi Therapeutics

CLOSING SOON: Developing precision therapies for genetic disorders affecting children

https://wefunder.com/mahzi.therapeutics

Total raised on Wefunder: 352522

Total investors: 147

Quick facts

  • $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
  • Completing patient enrollment in first-ever gene therapy clinical trial for Pitt-Hopkins syndrome
  • CEO with 20+ years of experience at Merck and rare disease pioneers Genzyme & Ultragenyx
  • Leadership team from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute
  • Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups
  • $60M raised from leading VCs Venrock, HealthCap, Droia Ventures & HBM Partners
  • ️​ Forbes 2026 Feature: “This Biotech Lets Families Invest in its Gene Therapy”
  • Targeting a $16B market with 800+ rare neurogenetic addressable disorders

Team profiles

Featured investor profiles

Invest in Mahzi Therapeutics

CLOSING SOON: Developing precision therapies for genetic disorders affecting children

FIRST GOAL HIT (You can still invest)

$34,537,221

raised from 156+ investors
INVESTMENT TERMS
Preferred Stock
$87.9M pre-money valuation $3.47 per share

Highlights

1
$16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
2
Completing patient enrollment in first-ever gene therapy clinical trial for Pitt-Hopkins syndrome
3
CEO with 20+ years of experience at Merck and rare disease pioneers Genzyme & Ultragenyx
4
Leadership team from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute

Related company links

Featured Investor

Team


Memo

Across the United States, families are caring for children with disabilities caused by rare neurogenetic disorders, often for decades. Many are told that nothing can be done beyond lifelong symptom management. These diseases are so overlooked that parents are often the ones digging through existing research to find potential treatments for their loved ones, because no one else will.

Mahzi Therapeutics is a clinical-stage biotech company developing precision genetic therapies for these rare neurogenetic disorders — devastating, diagnosable conditions characterized by disabilities that include autism, seizures, and developmental delays in children. Today, none of these disorders have an approved, life-changing treatment.

Families know their children, and our model exists to listen to them and execute on their behalf.

Mahzi partners with patient advocacy groups and academic researchers to turn validated science into potentially transformative therapies, so parents, aunts, and uncles can stop being drug developers and get back to being parents.

This year, Mahzi is set to complete enrollment in the first-ever gene therapy clinical trial for one of these debilitating disorders, Pitt-Hopkins syndrome.

Mahzi Therapeutics Founder & CEO Yael Weiss spent over 20 years developing therapies for rare and common diseases. With leadership from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute, the team has taken rare disease therapies from lab to approval at Merck, Genzyme, and Ultragenyx.

With $16M in non-dilutive financing and backing from institutional VCs including Venrock, HealthCap, and Droia Ventures, Mahzi Therapeutics is advancing a pipeline of precision therapies and building the next-generation biotech for the $16B+ rare neurological disease market.

Mahzi has progressed into human clinical testing, with the first patient dosed earlier this year in the first-ever gene therapy clinical trial for Pitt-Hopkins Syndrome. Mahzi is on track to enroll all 12 participants by the end of 2026.

Advancing a gene therapy into the clinic is a critical milestone, validating coordinated execution across clinical-scale manufacturing, regulatory process approvals, and complex trial operations.

1 in 10 Americans are living with rare diseases that impact their daily lives. For these families, this often means managing seizures throughout the night, interpreting the needs of a child who may never speak, and a calendar full of specialist visits that lead to few answers. Over 10,000 rare diseases have been identified, and fewer than 5% have any approved treatment.

The barrier to treatment often lies with the economics. Many genetic disorders affect patient populations too small to meet the commercial thresholds set by large pharmaceutical companies. As a result, even when the path to a potential therapy is clear, these disorders are less likely to be prioritized for therapeutic development.

To fill this gap, families and patient advocacy foundations have to fundraise to pay for academic research, partner with leading universities, and validate therapeutic approaches. But patient groups and families are not drug developers. In most cases, they lack the development expertise and the capital required to bring a therapy through regulatory approval, and even if they do, it becomes yet another challenge in their life on top of having a disabled child, a family to care for, and a day job.

Mahzi takes biology validated by patient groups and families and translates it into regulated, clinical-stage investigational therapies. Patient foundations and academic labs often conduct early research, identifying paths to developing therapies for single-gene disorders and providing initial proof-of-concept data that creates a reason to believe in a therapeutic path.

Mahzi then takes that information and applies its deep internal expertise in therapeutic development for neurodevelopmental disorders to move it into a clinical study. Building on proven science means less time and capital spent on early discovery so that each new program can reach the clinic sooner.

Mahzi develops precision genetic therapies for rare neurological disorders caused by mistakes in a single gene. For Pitt Hopkins, Mahzi’s investigational gene therapy is designed to deliver a working copy of the deficient gene so cells can make the protein they lack.

Each gene carries a cell instruction manual for producing a specific protein the body needs. When a page of that manual is missing, the cell can’t produce enough functional protein, and the effects show up as a disorder. Mahzi’s therapies deliver a working copy of the deficient protein directly into cells.

Mahzi’s investigational gene therapies use AAV9, a naturally occurring virus used in multiple FDA-approved gene therapies. The virus's original genetic material is replaced with a functional human gene, creating a single-administration therapy designed for durable protein expression.

Animal studies show promising results.

In a well-established Pitt Hopkins mouse model, Mahzi's gene therapy restored expression of the deficient protein, TCF4, after birth and drove measurable improvements, including better performance in learning, memory, and spatial navigation. The gene therapy increased neuronal connectivity and produced behavioral patterns closer to those of healthy littermates.

These results showed gene replacement could improve both molecular function and higher-order behavior in mice, a critical step toward human testing.

Rare neurological diseases represent a $16B+ market, and one of the fastest-growing segments within the $200B+ rare disease therapeutics space.

Advances in genetic testing are accelerating rare disease diagnosis. At the same time, FDA orphan drug incentives, including seven years of market exclusivity, tax credits, and expedited review, have made development economics increasingly attractive to investors.

Mahzi Therapeutics CEO Dr. Yael Weiss learned about this gene therapy when Pitt Hopkins Research Foundation President Audrey Davidow invited her to the foundation’s research update in 2020. There, the researcher who invented the gene therapy presented early data that demonstrated proof of concept for the Pitt Hopkins gene therapy. Mahzi later licensed the program, transferred the data and know-how, and advanced it to a clinical trial.

The result: the first-ever gene therapy trial for the disorder.

Mahzi's CEO brings 20+ years at Merck and rare disease pioneers Genzyme and Ultragenyx. A Termeer Fellow, Yael Weiss also led Mahzi to become the first recipient of the FamilieSCN2A Accelerator Award in 2025.

The leadership team brings industry expertise, with training from Stanford, Cambridge, Yale, UC Berkeley, and the Weizmann Institute, plus hands-on experience leading clinical trials, regulatory submissions, and gene therapy manufacturing.

Mahzi’s Board of Directors includes senior biotech executives who built Alnylam and Zogenix (acquired by global neurology company UCB for up to $1.9 billion) and investors with exits to Novo Nordisk, Merck, and Allergan - publicly traded pharma companies.

Each Mahzi drug represents a standalone commercial opportunity with limited competition.

These disorders often have no life-changing treatments; thus, an FDA-approved, one-time gene therapy could be priced based on the therapeutic impact it delivers, making each therapeutic a strong business on its own, even with a small patient population.

Mahzi projects $200M to $600M in peak annual revenue for each indication in its portfolio (not guaranteed).

With 800+ rare neurogenetic disorders potentially addressable through our approach, the platform can diversify its offering for many more treatments for these disorders. Each new program builds on the same preclinical, clinical, and regulatory playbook, so the path to market gets faster and more efficient with every new program Mahzi takes on.

Rare disease gene therapies with clinical validation have commanded major acquisition deal prices. Biopharma companies increasingly acquire or partner with teams that already have clinical progress, rather than developing rare disease assets internally, ultimately rewarding companies with validated clinical assets, novel indications, and efficient execution.

In this category, acquirers pay for clinical-stage assets and teams that can repeatedly execute across multiple indications. Mahzi meets these requirements.

Mahzi means “together” in Greek. We started this company with a simple belief: parents should not be embarking on a drug development journey on their own. Mahzi is empowered by patients and their families to develop therapies that address severe, debilitating disorders. These are families in the communities we partner with, and most of them are still waiting for a chance.

Invest in Mahzi today and help advance potential therapies for families who have waited too long for a solution.

wefunder.com/mahzitherapeutics/invest


Overview